Note AB (FRA:NQA) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... By GuruFocus

Note AB reported SEK 962 million in revenue, slightly above guidance, with an operating margin of 9.1% and order backlog up 11% year over year. However, organic growth was negative 6%, with weak performance in Western Europe, the U.K. and China, plus a 70% drop in Medtech from the largest customer. The STI acquisition is a positive strategic step for Security & Defence exposure, but management also flagged a weak start to Q1 2026 and no dividend this year due to recent investments.

Analysis

The market is likely misreading the signal in INTC: this is less about a generic AI capex cycle and more about a second-order re-acceleration in server CPU attach rates, which tends to show up before the headline AI accelerator winners get the full credit. If enterprise and cloud buyers are refreshing infrastructure to support AI inference, the CPU socket content can expand even when GPU budgets dominate the narrative, which is why the move can be broader and more durable than a one-day semiconductor pop. The key is whether this becomes a multi-quarter inventory pull rather than a one-off sentiment burst.

For NOTE, the important read-through is not the mixed print itself but the quality of backlog and the mix shift toward defense. The STI acquisition appears to be converting the business from a cyclical EMS grinder into a more embedded, security-linked manufacturing platform with higher switching costs and better pricing power. That said, the near-term optics are still fragile: weak Medtech and Europe exposure mean the market will likely penalize any slip in execution until Q2/Q3 proves that defense can offset the rest of the book.

The contrarian risk is that both names may be getting ahead of actual demand realization. For INTC, a CPU-led AI upgrade cycle can be delayed if hyperscalers keep extending server lifetimes or if AI workloads remain GPU-heavy longer than bulls expect. For NOTE, a backlog is only useful if supply execution and customer concentration don’t break again; the defense upside is real, but the business still has enough legacy drag that one bad quarter could reset multiple expansion expectations. Time horizon matters: INTC is a weeks-to-months catalyst, NOTE is a multi-quarter integration and mix story.

Key Decisions for Investors

• Long INTC vs. short SMH on a 1-3 month horizon: express a relative-value view that CPU/enterprise refresh can surprise to the upside even if the broader AI basket pauses; target a 2:1 reward/risk if the market rotates from accelerators into infrastructure.
• Buy INTC short-dated call spreads into any pullback over the next 2-4 weeks: use defined risk to capture a continuation move if guidance revisions start to reflect AI-adjacent server demand; exit if the pop fails to hold for 3-5 sessions.
• Long NOTE on weakness with a 3-6 month horizon, but pair against a more economically sensitive EMS peer if available: the defense mix shift and acquisition synergy story should re-rate faster than the legacy industrial/medtech drag fades.
• If holding NOTE, consider financing with upside call overwriting against a core long: backlog and defense exposure support the name, but near-term execution noise makes outright long exposure vulnerable to disappointing monthly sales prints.
• Avoid chasing both names after the initial move unless there is confirmation in subsequent channel checks: the risk/reward deteriorates quickly if the market is simply front-running a narrative rather than a visible order conversion cycle.